Michal Povazan
Overview
Explore the profile of Michal Povazan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
590
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Berger M, Garcia-Moreno H, Ferreira M, Hubener-Schmid J, Schaprian T, Wegner P, et al.
medRxiv
. 2025 Feb;
PMID: 39974031
Background: Spinocerebellar ataxia type 3 (SCA3) is an autosomal dominantly inherited adult-onset disease. We aimed to describe longitudinal changes in clinical and biological findings and to identify predictors for clinical...
2.
Rezende T, Petit E, Park Y, Tezenas du Montcel S, Joers J, DuBois J, et al.
Mov Disord
. 2024 Jul;
39(10):1856-1867.
PMID: 39056163
Background: Clinical trials for upcoming disease-modifying therapies of spinocerebellar ataxias (SCA), a group of rare movement disorders, lack endpoints sensitive to early disease progression, when therapeutics will be most effective....
3.
London A, Richter M, Sjoberg K, Wewer Albrechtsen N, Povazan M, Drici L, et al.
Am J Clin Nutr
. 2024 Jun;
120(2):283-293.
PMID: 38914224
Background: Intrahepatic triacylglycerol (liver TG) content is associated with hepatic insulin resistance and dyslipidemia. Liver TG content can be modulated within days under hypocaloric conditions. Objectives: We hypothesized that 4...
4.
Madsen M, Povazan M, Wiggermann V, Lundell H, Blinkenberg M, Romme Christensen J, et al.
Neurology
. 2024 Jun;
103(1):e209543.
PMID: 38870443
Background And Objectives: Cortical lesions contribute to disability in multiple sclerosis (MS), but their impact on regional neurotransmitter levels remains to be clarified. We tested the hypothesis that cortical lesions...
5.
Ferreira M, Schaprian T, Kugler D, Reuter M, Deike-Hoffmann K, Timmann D, et al.
Cerebellum
. 2024 Mar;
23(4):1530-1531.
PMID: 38446346
No abstract available.
6.
Ferreira M, Schaprian T, Kugler D, Reuter M, Deike-Hoffmann K, Timmann D, et al.
Cerebellum
. 2024 Feb;
23(4):1521-1529.
PMID: 38363498
Cerebellar atrophy is the neuropathological hallmark of most ataxias. Hence, quantifying the volume of the cerebellar grey and white matter is of great interest. In this study, we aim to...
7.
Ferreira M, Schaprian T, Kugler D, Reuter M, Deike-Hoffmann K, Timmann D, et al.
Res Sq
. 2023 Nov;
PMID: 38014351
Background: Cerebellar atrophy is the neuropathological hallmark of most ataxias. Hence, quantifying the volume of the cerebellar grey and white matter is of great interest. In this study, we aim...
8.
Faber J, Berger M, Wilke C, Hubener-Schmid J, Schaprian T, Santana M, et al.
Ann Neurol
. 2023 Nov;
95(2):400-406.
PMID: 37962377
Spinocerebellar ataxia type 3/Machado-Joseph disease is the most common autosomal dominant ataxia. In view of the development of targeted therapies, knowledge of early biomarker changes is needed. We analyzed cross-sectional...
9.
Mejdahl Nielsen M, Petersen E, Fenger C, Orngreen M, Siebner H, Boer V, et al.
Mol Genet Metab
. 2023 Sep;
140(3):107694.
PMID: 37708665
Creatine transporter deficiency (CTD), caused by pathogenic variants in SLC6A8, is the second most common cause of X-linked intellectual disability. Symptoms include intellectual disability, epilepsy, and behavioral disorders and are...
10.
Ozdemir I, Ganji S, Gillen J, Etyemez S, Povazan M, Barker P
Magn Reson Med
. 2023 May;
90(3):814-822.
PMID: 37249071
Purpose: To develop a 3D downfield (DF) MRSI protocol with whole brain coverage and post-processing pipeline for creation of metabolite maps. Methods: A 3D, circularly phase-encoded version of the previously...